Vaccination Strategies against Malaria: Novel carrier(s) more than a tour de force

Journal of Controlled Release

Volumn 162, Issue 1, 2012, Pages 242-254

  Tyagi, Rajeev K ^a   Garg, Neeraj K ^b,c   Sahu, Tejram ^d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b DR H S GOUR UNIVERSITY   (India)

^c Shantha Biotechnics Limited   (India)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adjuvant; Cationic lipid; Hemagglutinin; Immunogenicity; Immunopotentiating reconstituted influenza virosomes; Microsphere; pH sensitive liposome; Subunit vaccines; TAP (Transcription activator protein); Transfection; Virosomes

Indexed keywords

ADJUVANT; CATIONIC LIPIDS; HEMAGGLUTININ; IMMUNOGENICITY; IMMUNOPOTENTIATING RECONSTITUTED INFLUENZA VIROSOMES; PH-SENSITIVE LIPOSOMES; SUBUNIT VACCINE; TRANSCRIPTION ACTIVATORS; TRANSFECTION; VIROSOMES;

ANTIGENS; DISEASES; DNA; GENE TRANSFER; MICROSPHERES;

VACCINES;

APICAL MEROZOITE ANTIGEN 1; CIRCUMSPOROZOITE PROTEIN; DENDRIMER; DNA VACCINE; ERYTHROCYTE BINDING ANTIGEN 175; ERYTHROCYTE MEMBRANE PROTEIN 1; GLYCOPHORIN BINDING PROTEIN 130; HISTIDINE RICH PROTEIN 2; LIPOPLEX; LIPOSOME; LIVE VACCINE; LIVER STAGE SPECIFIC ANTIGEN 1; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; MICROSPHERE; NAKED DNA; NANOPARTICLE; PARASITE ANTIGEN; PLASMID DNA; POLYMER; RECOMBINANT VACCINE; RHOPTRY ASSOCIATED PROTEIN 1; RHOPTRY ASSOCIATED PROTEIN 2; RING INFECTED ERYTHROCYTE SURFACE ANTIGEN; SERINE REPEAT ANTIGEN; SPOROZOITE SURFACE PROTEIN 2; SUBUNIT VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME;

ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DNA TRANSFECTION; DRUG DESIGN; DRUG FORMULATION; DRUG POTENCY; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; HUMAN; HUMORAL IMMUNITY; LIPOSOMAL GENE DELIVERY SYSTEM; MALARIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PRIORITY JOURNAL; PROTIST LIFE CYCLE STAGE; REVIEW; VACCINATION;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MALARIA; MALARIA VACCINES; PLASMODIUM; VACCINATION; VACCINES, DNA;

EID: 84864690638     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.04.037     Document Type: Review

References (169)

1. WHO World Malaria Report 2010 2010 www.who.int/malaria/ world-malaria-report-2010/en/index.html
2. B. Greenwood Malaria vaccines. Evaluation and implementation Acta Trop. 95 2005 298 304
3. N.J. White Drug resistance in malaria Br. Med. Bull. 54 1998 703 715
4. C.F. Curtis Should the use of DDT be revived for malaria vector control? Biomedica 22 2002 455 461
5. E. Malkin, F. Dubovsky, and M. Moree Progress towards the development of malaria vaccines Trends Parasitol. 22 2006 292 295
6. R.S. Nussenbzweig, J. Vanderberg, H. Most, and C. Orton Protective immunity produced by the injection of X-irradiated sporozoite of Plasmodium berghei Nature 216 1967 160 162
7. D.F. Clyde, V.C. McCarthy, R.M. Miller, and R.B. Hornick Specificity of protection of man immunized against sporozoite induced falciparum malaria Am. J. Med. Sci. 266 1973 398 403
8. D.F. Clyde, V.C. McCarthy, R.M. Miller, and J.P. Vanderberg Specificity of protection of man immunized against sporozoite induced falciparum malaria Am. J. Med. Sci. 266 1973 169 177
9. D.F. Clyde, V.C. McCarthy, R.M. Miller, and W.E. Woodward Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites Am. Trop. Med. Hyg. 24 1975 397 401
10. R.W. Gwadz, A.H. Cochrane, V. Nussenbzweig, and R.S. Nussenbzweig Preliminary studies on vaccination of rhesus monkeys with irradiated sporozoites of Plasmodium knowleski and characterization of surface antigens of these parasites Bull. World Health Organ. 57 1979 165 173
11. Malcolm J. Gardner, Neil Hall, Eula Fung, Owen White, Matthew Berriman, and Bart Barrell Genome sequence of the human malaria parasite Plasmodium falciparum Nature 419 2002 498 511
12. D.L. Doolan, and S.L. Hoffman DNA based vaccines against malaria: status and promise of the multistage malaria DNA Vaccine Operation Int. J. Parasitol. 31 2006 753 762
13. W.E. Collins, and J.W. Barnwell Plasmodium knowlesi: finally being recognized J. Infect. Dis. 199 2009 1107 1108
14. J. Cox-Singh, T.M. Davis, K.S. Lee, S.S. Shamsul, A. Matusop, S. Ratnam, H.A. Rahman, D.J. Conway, and B. Singh Plasmodium knowlesi malaria in human is widely distributed and potentially life threatening Clin. Infect. Dis. 46 2008 165 171
15. B. Singh, L. Kim Sung, A. Matusop, A. Radhakrishnan, S.S. Shamsul, J. Cox-Singh, A. Thomas, and D.J. Conway A large focus of naturally acquired Plasmodium knowlesi infections in human beings Lancet 363 2004 1017 1024
16. N.J. White Plasmodium knowlesi: the fifth human malaria parasite Clin. Infect. Dis. 46 2008 172 173
17. F. Dubovsky, and N.R. Rabinovich Malaria vaccines S.A. Plotkin, W.A. Orenstein, Vaccines 4th ed. 2004 Saunders Philadelphia 1283 1289
18. M.P. Girard, Z.H. Reed, M. Friede, and M.P. Kieny A review of human vaccine research and development: Malaria Vaccine 25 2007 1567 1580
19. M.A. Herrera, and S. Herrera Plasmodium vivax malaria vaccine development Mol. Immunol. 38 2001 443 455
20. I.E. McGregor The passive transfer of human malarial immunity Am.J.Trop. Med. Hyg. 13 1964 237 239
21. J.E. Egan, S.L. Hoffman, J.D. Haynes, J.C. Sadoff, I. Schneider, and G.E. Grau Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites Am.J.Trop. Med. Hyg. 49 1993 166 173
22. S.L. Hoffman, L.M. Goh, T.C. Luke, I. Schneider, T.P. Le, and D.L. Doolan Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites J. Infect. Dis. 185 2002 1155 1164
23. K.N. Mendis, Y.D. Munesinghe, Y.N. de Silva, I. Keragalla, and R. Carter Malaria transmission-blocking immunity induced by natural infections of Plasmodium vivaxin humans Infect. Immun. 55 1987 369 372
24. H. Hisaeda, A.W. Stowers, T. Tsuboi, W.E. Collins, J.S. Sattabongkot, N. Suwanabun, M. Torii, and D.C. Kaslow Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes Infect. Immun. 68 2000 6618 6623
25. A.V. Hill Pre-erythrocytic malaria vaccines: towards greater efficacy Nat. Rev. Immunol. 6 2006 21 32
26. T.C. Luke, and S.L. Hoffman Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine J. Exp. Biol. 206 2003 3803 3808
27. M.F. Good Vaccine-induced immunity to malaria parasites and the need for novel strategies Trends Parasitol. 21 2005 29 34
28. A.K. Mueller, M. Labaied, S.H. Kappe, and K. Matuschewski Genetically modified Plasmodium parasites as a protective experimental malaria vaccine Nature 433 2005 164 167
29. A.V. Hill, C.E. Allsopp, and D. Kwiatkowski Common west African HLA antigens are associated with protection from severe malaria Nature 352 1991 595 600
30. W.H. Reece, M. Pinder, P.K. Gothard, P. Milligan, K. Bojang, T. Doherty, M. Plebanski, P. Akinwunmi, S. Everaere, K.R. Watkins, G. Voss, N. Tornieporth, A. Alloueche, B.M. Greenwood, K.E. Kester, K.P. McAdam, J. Cohen, and A.V. Hill A CD4 + T cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease Nat. Med. 10 2004 406 410
31. E.H. Nardin, V. Nussenzweig, and R.S. Nussenzweig Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax J. Exp. Med. 156 1982 20 30
32. E.H. Nardin, and R.S. Nussenzweig T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages Annu. Rev. Immunol. 11 1993 687 727
33. J.E. Egan Efficacy of murine malaria sporozoite vaccines: implications for humanvaccine development Science 236 1987 453
34. P. Sharma, A. Bharadwaj, V.K. Bhasin, V.N. Sailaja, and V.S. Chauhan Antibodies to a conserved motifpeptide sequence of the Plasmodium falciparum thrombospondin-related anonymousprotein and circumsporozoite protein recognize a 78-kilodalton protein in the asexual bloodstages of the parasite and inhibit merozoite invasion in vitro Infect. Immun. 64 6 1996 2172 2179
35. C. Guerln-Marchand A liver stage-specific antigen of Plasmodium falciparum characterized by gene cloning Nature 32 1987 164 167
36. K. Tanabe, M. Mackay, M. Goman, and J.G. Scaife Allelic dimorphism in a surface antigen gene ofthe malaria parasite Plasmodium falciparum J. Mol. Biol. 195 2 1987 273 287
37. J.T. Clark, S. Donachie, R. Anand, C.F. Wilson, H.G. Heidrich, and J.S. McBride 46-53 kilodalton glycoprotein from the surface of Plasmodium falciparum merozoites Mol. Biochem. Parasitol. 32 1 1989 15 24
38. B.K. Sim, P.A. Orlandi, J.D. Haynes, F.W. Klotz, J.M. Carter, D. Camus, M.E. Zegans, and J.D. Chulay Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion J. Cell Biol. 111 1990 1877 1884
39. B.K. Sim, C.E. Chitnis, K. Wasniowska, T.J. Hadley, and L.H. Miller Receptor and ligand domains forinvasion of erythrocytes by Plasmodium falciparum Science 264 5167 1994 1941 1944
40. R.L. Coppel, A.F. Cowman, R.F. Anders, A.E. Bianco, R.B. Saint, K.R. Lingelbach, D.J. Kemp, and G.V. Brown Immune sera recognize on erythrocytes Plasmodium falciparum antigen composed of repeated amino acid sequences Nature 310 5980 1984 789 792
41. J.G. Culvenor, K.P. Day, and R.F. Anders Plasmodium falciparum ring-infected erythrocyte surfaceantigen is released from merozoite dense granules after erythrocyte invasion Infect. Immun. 59 3 1991 1183 1187
42. P. Delplace, A. Bhatia, M. Cagnard, D. Camus, G. Colombet, A. Debrabant, J.F. Dubremetz, N. Dubreuil, G. Prensier, and B. Fortier Protein p126: a parasitophorous vacuole antigen associated with the release of Plasmodium falciparum merozoites Biol. Cell 64 2 1988 215 221
43. J.E. Suarez, M. Urquiza, H. Curtidor, L.E. Rodriguez, M. Ocampo, E. Torres, F. Guzman, and M.E. Patarroyo A GBP 130 derived peptide from Plasmodium falciparum binds to human erythrocytes and inhibits merozoite invasion in vitro Mem. Inst. Oswaldo Cruz, Rio de Janeiro 95 4 2000 Jul./Aug.
44. M.G. Peterson, V.M. Marshall, J.A. Smythe, P.E. Crewther, A. Lew, A. Silva, R.F. Anders, and D.J. Kemp Integral membrane protein located in the apical complex of Plasmodium falciparum Mol. Cell. Biol. 9 7 1989 3151 3154
45. A.P. Waters, A.W. Thomas, J.A. Deans, G.H. Mitchell, D.E. Hudson, L.H. Miller, T.F. McCutchan, and S. Cohen A merozoite receptor protein from Plasmodium knowlesi is highly conserved anddistributed throughout Plasmodium J. Biol. Chem. 265 29 1990 17974 17979
46. A. Kilejian, and J.B. Jensen A histidine-rich protein from Plasmodium falciparum and its interaction with membranes Bull. World Health Organ. 55 1977 191 197
47. J.A. Cooper, L.T. Ingram, G.R. Bushell, C.A. Fardoulys, D. Stenzel, L. Schofield, and A.J. Saul The140/130/105 kilodalton protein complex in the rhoptries of Plasmodium falciparum consists of discrete polypeptides Mol. Biochem. Parasitol. 2 1988 251 260
48. J.H. Leech, J.W. Barnwell, L.H. Miller, and R.J. Howard Identification of a strain-specific malaria lantigen exposed on the surface of Plasmodium falciparum-infected erythrocytes J. Exp. Med. 159 1984 1567 1575
49. X.Z. Su, V.M. Heatwole, S.P. Wertheimer, F. Guinet, J.A. Herrfeldt, D.S. Peterson, J.A. Ravetch, and T.E. Wellems The large diverse gene family var encodes proteins involved in cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes Cell 82 1995 89 100
50. P.J. Barr, K.M. Green, H.L. Gibson, I.C. Bathurst, I.A. Quakyi, and D.C. Kaslow Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals JEM 174 1991 1203 1208
51. D.F. Clyde, V.C. McCarthy, M.R. Miller, and W.F. Woodward Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites Am.J.Trop. Med. Hyg. 24 1975 397 401
52. K.H. Rieckmann, R.L. Beaudoin, J.S. Cassells, and K.W. Sell Use of attenuated sporozoites in the immunization of human volunteers against falciparum malaria Bull. World Health Organ. 57 1979 261 265
53. M. Tsuji, P. Mombaerts, L. Lefrancois, R.S. Nussenzweig, F. Zavala, and S. Tonegawa Gamma delta T cells contribute to immunity against the liver stages of malaria in alpha beta T-cell-deficient mice Proc. Natl. Acad. Sci. U. S. A. 91 1994 345 349
54. M.F. Good, and D.L. Doolan Immune effector mechanisms in malaria Curr. Opin. Immunol. 11 1999 412 419
55. E. Nardin, F. Zavala, V. Nussenzweig, and R.S. Nussenzweig Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials Parassitologia 41 1999 397 402
56. G. Gonzalez-Aseguinolaza, C. de Oliveira, M. Tomaska, S. Hong, O. Bruna-Romero, and T. Nakayama Alpha-galactosylceramide activated V alpha 14 natural killer T cells mediate protection against murine malaria Proc. Natl. Acad. Sci. USA 97 2000 8461 8466
57. P. Sun, R. Schwenk, K. White, J.A. Stoute, J. Cohen, and W.R. Ballou Protective immunity induced with malaria vaccine, RTS, S, is linked to Plasmodium falciparum circum-sporozoite protein specific CD4 + and CD8 + T cells producing IFN-gamma J. Immunol. 171 2003 6961 6967
58. G.A. González, Y.N. Molano, E.M. Esteban, D. Rodríguez, J.R. Rodríguez, P. Palese, A. García-Sastre, and R.S. Nussenzweig Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii J. Virol. 77 2003 11859 11866
59. M. Tsuji, C.C. Bergmann, Y. Takita-Sonoda, K. Murata, E.G. Rodrigues, R.S. Nussenzweig, and F. Zavala Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice J. Virol. 72 1998 6907 6910
60. O. Bruña-Romero, G. González-Aseguinolaza, J.C. Hafalla, M. Tsuji, and R.S. Nussenzweig Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen Proc. Natl. Acad. Sci. U. S. A. 98 2001 11491 11496
61. P. Bejon, N. Peshu, S.C. Gilbert, B.S. Lowe, C.S. Molyneux, and J. Forsdyke Safety profile of the viral vectors of attenuated fowl pox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 pre-erythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya Clin. Infect. Dis. 42 2006 1102 1110
62. D.P. Webster, S. Dunachie, S. McConkey, I. Poulton, A.C. Moore, and M. Walther Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers Vaccine 24 2006 3026 3034
63. S.E. Parker, D. Monteith, H. Horton, R. Hof, P. Hernandez, and A. Vilalta Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine GeneTher. 8 2001 1011 1023
64. R. Wang, D.L. Doolan, T.P. Le, R.C. Hedstrom, K.M. Coonan, and Y. Charoenvit Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine Science 282 1998 476 480
65. R. Wang, J. Epstein, F.M. Baraceros, E.J. Gorak, Y. Charoenvit, and D.J. Carucci Induction of CD4 (+) T cell-dependent CD8 (+) type 1 responses in humans by a malaria DNA vaccine Proc. Natl. Acad. Sci. U. S. A. 98 2001 10817 10822
66. A.C. Moore, and A.V. Hill Progress in DNA-based heterologous prime-boost immunization strategies for malaria Immunol. Rev. 199 2004 126 143
67. A.V. Hill, W. Reece, P. Gothard, V. Moorthy, M. Roberts, and K. Flanagan DNA-based vaccines for malaria: a heterologous prime-boost immunization strategy Dev. Biol. (Basel) 104 2000 171 179
68. V.S. Moorthy, E.B. Imoukhuede, P. Milligan, K. Bojang, S. Keating, and P. Kaye A randomized, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults PLoS Med. 1 2004 e33
69. S.J. Dunachie, M. Walther, J.E. Epstein, S. Keating, T. Berthoud, and L. Andrews A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge Infect. Immun. 74 2006 5933 5942
70. D.P. Webster, S. Dunachie, J.M. Vuola, T. Berthoud, S. Keating, and S.M. Laidlaw Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara Proc. Natl. Acad. Sci. U. S. A. 102 2005 4836 4841
71. P. Bejon, J. Mwacharo, O.K. Kai, S. Todryk, S. Keating, and T. Lang Immunogenicity of the candidate malaria vaccines FP9 and modified Vaccine a virus Ankara encoding the pre-erythrocytic antigen METRAP in 1-6 year old children in a malaria endemic area Vaccine 24 2006 4709 4715
72. J.D. Kurtis, M.R. Hollingdale, A.J. Luty, D.E. Lanar, U. Krzych, and P.E. Duffy Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine Trends Parasitol. 17 2001 219 223
73. P. Daubersies, A.W. Thomas, P. Millet, K. Brahimi, J.A. Langermans, B. Ollomo, L. BenMohamed, B. Slierendregt, W. Eling, A. Van Belkum, G. Dubreuil, J.F. Meis, C. Guérin-Marchand, S. Cayphas, J. Cohen, H. Gras-Masse, and P. Druilhe Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3 Nat. Med. 6 2000 1258 1263
74. D.A. Barnes, W. Wollish, R.G. Nelson, J.H. Leech, and C. Petersen Plasmodium falciparum: D260, an intra-erythrocytic parasite protein, is a member of the glutamic acid dipeptide-repeat family of proteins Exp. Parasitol. 81 1995 79 89
75. G. Patarroyo, L. Franco, R. Amador, L.A. Murillo, C.L. Rocha, and M. Rojas Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years Vaccine 10 1992 175 178
76. P.L. Alonso, T.A. Smith, J.R. Armstrong-Schellenberg, A.Y. Kitua, H. Masanja, and R. Hayes Duration of protection and age-dependence of the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of Plasmodium falciparum J. Infect. Dis. 174 1996 367 372
77. P.L. Alonso, T. Smith, J.R. Schellenberg, H. Masanja, S. Mwankusye, and H. Urassa Randomized trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania Lancet 344 1994 1175 1181
78. A.F. Egan, J. Morris, and G. Barnish Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1 J. Infect. Dis. 173 1996 765 769
79. A.F. Egan, P. Burghaus, P. Druilhe, A.A. Holder, and E.M. Riley Human antibodies to the 19 kDa C terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro Parasite Immunol. 21 1999 133 139
80. R.A. O'Donnell, T.F. de Koning-Ward, and R.A. Burt Antibodies against merozoite surface protein (msp)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria J. Exp. Med. 193 2001 1403 1412
81. A.A. Holder, J.A. Guevara Patino, and C. Uthaipibull Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria Parasitologia 41 1999 409 414
82. W.A. Keitel, K.E. Kester, and R.L. Atmar Phase I trial of two recombinant vaccines containing the 19 kDacarboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid Vaccine 18 1999 531 539
83. D.C. Kaslow Transmission-Blocking Vaccine S.L. Hoffman, Malaria Vaccine Development: A Multi-Immune Response Approach 1996 American Society for Microbiology Washington, DC 181 227
84. R. Carter, K.N. Mendis, L.H. Miller, L. Molineaux, and A. Saul Malaria transmission-blocking vaccines - how can their development be supported? Nat. Med. 6 2000 241 244
85. H. Hisaeda, A.W. Stowers, T. Tsuboi, W.E. Collins, J.S. Sattabongkot, and N. Suwanabun Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes Infect. Immun. 68 2000 6618 6623
86. E.M. Malkin, A.P. Durbin, D.J. Diemert, J. Sattabongkot, Y. Wu, and K. Miura Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria Vaccine 23 2005 3131 3138
87. P.J. Bustamante, D.C. Woodruff, J. Oh, D.B. Keister, O. Muratova, and K.C. Williamson Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity Parasite Immunol. 22 2000 373 380
88. D.G. Becker, V. Moulin, B. Pajak, C. Bruck, M. Francotte, C. Thiriart, J. Urbain, and M. Moser The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells Int. Immunol. 12 2000 807 815
89. J. Aucouturier, L. Dupuis, and V. Ganne Adjuvant designed for veterinary and human vaccines Vaccine 19 2001 2666 2672
90. T. Lindahl, A.G. Joseph, and G.M. Edelman Deoxyribonucleaseiv: a new exonuclease from mammalian tissues PNAS 1968 597 603
91. A.D. Bangham, M.M. Standish, and N. Miller Cation permeability of phospholipid model membranes: effect of narcotics Nature 208 1965 1295 1297
92. A.G. Allison, and G. Gregoriadis Liposomes as immunological adjuvants Nature 252 1974 252
93. I. Rosenkrands, M.E. Agger, W.A. Olsen, S.K. Korsholm, S.C. Andersen, T.K. Jensen, and P. Andersen Cationic Liposomes Containing Mycobacterial Lipids: a New Powerful Th1 Adjuvant System Infect. Immun. 73 2005 5817 5826
94. M. Owais, and C.M. Gupta Liposome-mediated cytosolic delivery of macromolecules and its possible use in vaccine development Eur. J. Biochem. 267 2000 3946 3956
95. S.P. Vyas, R.S. Jadon, A.K. Goyal, N. Mishra, P.N. Gupta, K. Khatri, and R. Tyagi pH sensitive liposomes enhances immunogenicity of 19 kDa carboxyl-terminal fragment of Plasmodium falciparum Int. J. Pharm. Sci. Nanotech. 1 2007 78 86
96. S. Tiwari, A.K. Goyal, K. Khatri, P.N. Gupta, N. Mishra, and S.P. Vyas Gel core liposomes: an advanced carrier for improved vaccine delivery J. Microencapsulation 26 2009 75 82
97. S. Tiwari, A.K. Goyal, N. Mishra, K. Khatri, B. Vaidya, A. Mehta, Y. Wu, and S.P. Vyas Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine J. Control. Release 140 2009 157 165
98. N. Meykadeh, A. Mirmohammadsadegh, Z. Wang, E.B. Schakarjan, and U.R. Hengge Topical application of plasmid DNA to mouse and human skin J. Mol. Med. 83 2005 897 903
99. M.J. Choi, and H.I. Maibach Topical vaccination of DNA antigens: Topical Delivery of DNA antigens Skin Pharmacol. Appl. Skin Physiol. 16 2003 271 282
100. R.P. Singh, P. Singh, V. Mishra, D. Prabakaran, and S.P. Vyas Vesicular systems for non-invasive topical immunization: rationale and prospects Indian J. Pharmacol. 34 2002 301 310
101. J. Bramson, K. Dayball, C. Evelegh, Y.H. Wan, D. Page, and A. Smith Enabling topical immunization via microporation: a novel method for pain free and needle free delivery of adenovirus-based vaccines Gene Ther. 10 2003 251 260
102. J.D. Toussignant, A.L. Gates, L.A. Ingram, C.L. Johnson, J.B. Nietupski, S.H. Chen, S.J. Eastman, and R.K. Scheule Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice Hum. Gene Ther. 11 2000 2493 2513
103. Y.K. Song, F. Liu, S. Chu, and D. Liu Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration Hum. Gene Ther. 8 1997 1585 1594
104. S. Li, P.S. Wu, M. Whitmore, E.J. Loeffert, L. Wang, S.C. Watkins, B.R. Pitt, and L. Huang Effect of immune response on gene transfer to the lung via systemic administration of cationic lipid vectors Am. J. Physiol. 276 1999 L796 L804
105. S. Dokka, D. Toledo, X. Shi, V. Castranova, and Y. Rojanasakul Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes Pharm. Res. 17 2000 521 525
106. R.D. Kanter, M. Monshouwer, D.K. Meijer, and G.M. Groothuis Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues Curr. Drug Metab. 1 2002 39 59
107. S.D. Patil, D.G. Rhodes, and D.J. Burgess Anionic Liposomal Delivery System for DNA Transfection AAPS J. 6 2004 1 10
108. V.P. Torchilin, T.S. Levchenko, R. Rammohan, N. Volodina, B.P. Sternberg, and G.M.G. D'Souza Cell transfection in vitro and in vivo with non-toxic TAT peptide-liposome-DNA complexes Proc. Natl. Acad. Sci. U. S. A. 100 2003 1972 1977
109. D. Felnerova, J.F. Viret, R. Glück, and C. Moser Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs Curr. Opin. Biotechnol. 15 2004 518 529
110. L. Zhang, F.X. Gu, J.M. Chan, A.Z. Wang, R.S. Langer, and O.C. Farokhzad Nanoparticles in Medicine: Therapeutic Applications and Developments Clin. Pharmacol. Ther. 83 2008 761 769
111. R. Gluck, R. Mischler, S. Brantschen, M. Just, B. Althaus, and S.J. Cryz Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A J. Clin. Invest. 90 1992 2491 2495
112. C. Moser, I.C. Metcalfe, and J.F. Viret Virosomal adjuvanted antigen delivery systems Expert Rev. Vaccines 2 2003 189 196
113. R. Gluck, and I.C. Metcalfe Novel approaches in the development of immunopotentiating reconstituted influenza virosomes as efficient antigen carrier systems Vaccine 21 2003 611 615
114. L. Bungener, A. Huckriede, J. Wilschut, and T. Daemen Delivery of protein antigens to the immune system by fusion-active virosomes: a comparison with liposomes and ISCOMs Biosci. Rep. 22 2002 323 338
115. R. Zurbriggen Immunostimulating reconstituted influenza virosomes Vaccine 21 2003 921 924
116. R. Zurbriggen, and R. Gluck Immunogenicity of IRIV- versus alum-adjuvanted diphtheria and tetanus toxoid vaccines in influenza primed mice Vaccine 17 1999 1301 1305
117. R. Zurbriggen, I. Novak-Hofer, A. Seelig, and R. Gluck IRIV-adjuvanted hepatitis A vaccine: in vivo absorption and biophysical characterization Prog. Lipid Res. 39 2000 3 18
118. T. Fehr, M.F. Bachmann, E. Bucher, U. Kalinke, F.E. Di Padova, A.B. Lang, H. Hengartner, and R.M. Zinkernagel Role of repetitive antigen patterns for induction of antibodies against antibodies J. Exp. Med. 185 1997 1785 1792
119. A. Huckriede, L. Bungener, W. ter Veer, M. Holtrop, T. Daemen, A.M. Palache, and J. Wilschut Influenza virosomes: combining optimal presentation of hemagglutinin with immunopotentiating activity Vaccine 21 2003 925 931
120. M.F. Bachmann, H. Hengartner, and R.M. Zinkernagel T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: role of antigen patterns in B cell induction? Eur. J. Immunol. 25 1995 3445 3451
121. R. Schumacher, M. Adamina, R. Zurbriggen, M. Bolli, E. Padovan, P. Zajac, M. Heberer, and G.C. Spagnoli Influenza virosomes enhance class I restricted CTL induction through CD4 + T cell activation Vaccine 22 2004 714 723
122. M.S. Mueller, A. Renard, F. Boato, D. Vogel, M. Naegeli, R. Zurbriggen, J.A. Robinson, and G. Pluschke Induction of parasite growth inhibitory antibodies by a virosomal formulation of a peptidomimetic of loop I from domain III of Plasmodium falciparum apical membrane antigen 1 Infect. Immun. 71 2003 4749 4758
123. I.P. Hunziker, B. Grabscheid, R. Zurbriggen, R. Gluck, W.J. Pichler, and A. Cerny In vitro studies of core peptide-bearing immunopotentiating reconstituted influenza virosomes as a non-live prototype vaccine against hepatitis C virus Int. Immunol. 14 2002 615 626
124. M.G. Cusi, R. Zurbriggen, P. Correale, M. Valassina, C. Terrosi, L. Pergola, P.E. Valensin, and R. Gluck Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity Vaccine 20 2002 3436 3442
125. P. Correale, M.G. Cusi, M. Sabatino, L. Micheli, D. Pozzessere, C. Nencini, P.E. Valensin, R. Petrioli, G. Giorgi, R. Zurbriggen, R. Gluck, and G. Francini Tumour-associated antigen (TAA)-specific cytotoxic T cell (CTL) response in vitro and in a mouse model, induced by TAA-plasmids delivered by influenza virosomes Eur. J. Cancer 37 2001 2097 2103
126. M.G. Cusi, S. Fischer, R. Sedlmeier, M. Valassina, P.E. Valensin, M. Donati, and W.J. Neubert Localization of a new neutralizing epitope on the mumps virus hemagglutinin-neuraminidase protein Virus Res. 74 2001 133 137
127. A. Scardino, P. Correale, H. Firat, M. Pellegrini, K. Kosmatopoulos, P. Opolon, P. Alves, R. Zurbriggen, R. Gluck, F.A. Lemonnier, G. Francini, and M.G. Cusi In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse Br. J. Cancer 89 2003 199 205
128. D.T. O'Hagan, H. Jeffery, and S.S. Davis Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles Vaccine 11 1993 965 969
129. D.T. O'Hagan, D. Rafferty, S. Wharton, and L. Illum Intravaginal immunization in sheep using a bio-adhesive microsphere antigen delivery system Vaccine 11 1993 660 664
130. Y. Men, C. Thomasin, H.P. Merkle, B. Gander, and G. Corradin A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody response similar or superior to those obtained with aluminum hydroxide Vaccine 7 1995 683 689
131. E. Mataa, A.M. Carcaboso, R.M. Hernandez, M. Igartua, G. Corradin, and J.L. Pedraz Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice Vaccine 25 2007 877 885
132. A.M. Carcaboso, R.M. Hernández, M. Igartua, J.E. Rosas, M.E. Patarroyo, and J.L. Pedraz Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles Vaccine 22 2004 1423 1432
133. P. Johansen, Y. Men, H.P. Merkle, and B. Gander Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination Eur. J. Pharm. Biopharm. 50 2000 129 146
134. C. Thomasin, G. Corradin, Y. Men, H.P. Merkle, and B. Gander Tetanus toxoid and synthetic malaria antigen containing poly (lactide)/poly (lactide-co-glycolide) microspheres: importance of polymer degradation and antigen release for immune response J. Control. Release 41 1996 131 145
135. Y. Men, H. Tamber, R. Audran, B. Gander, and G. Corradin Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres Vaccine 15 1997 1405 1412
136. E. Walter, D. Dreher, M. Kok, L. Thiele, S.G. Kiama, P. Gehr, and H.P. Merkle Hydrophilic poly (dl-lactide-co-gylcolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells J. Control. Release 76 2001 149 168
137. S. Prior, B. Gander, N. Blarer, H.P. Merkle, M.L. Subira, J.M. Irache, and C. Gamazo In vitro phagocytosis and monocyte-macrophage activation with poly (lactide) and poly (lactide-co-glycolide) microspheres Eur. J. Pharm. Sci. 15 2002 197 207
138. L. Lunsford, U. McKeever, V. Eckstein, and M.L. HedleyTissue distribution and persistence in mice of plasmid DNA encapsulated in PLGA-based microsphere delivery vehicle J. Drug Target. 8 2000 39 50
139. K.D. Newman, P. Elamanchili, G.S. Kwon, and J. Samuel Uptake of poly (d, l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo J. Biomed. Mater. Res. 60 2002 480 486
140. S. Jilek, M. Ulrich, H.P. Merkle, and E. Walter Composition and surface charge of DNA-loaded microparticles determine maturation and cytokine secretion in human dendritic cells Pharm. Res. 21 2004 1240 1247
141. J. Banchereau, B. Briere, C. Caux, J. Davoust, S. Lebecque, Y.J. Liu, B. Pulendran, and K. Palucka Immunobiology of dendritic cells Annu. Rev. Immunol. 18 2000 767 811
142. D.T. Hagan, M. Singh, and J.B. Ulmer Microparticle based technologies for vaccines Methods 40 2006 10 19
143. X. Wu, B. Ding, and J. Gao Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy Int. J. Nanomed. 6 2011 1747 1756
144. K.C. Cho, S.H. Choi, and T.G. Park Low molecular weight PEI conjugated pluronic copolymer: useful additive for enhancing gene transfection efficiency Macromol. Res. 14 3 2006 348 353
145. K. Lee, K.H. Bae, Y. Lee, S.H. Lee, C.H. Ahn, and T.G. Park Pluronic/polyethylenimine shell crosslinked nanocapsules with embedded magnetite nanocrystals for magnetically triggered delivery of siRNA Macromol. Biosci. 10 3 2010 239 245
146. U. Lungwitz, M. Breunig, T. Blunk, and A. Göpferich Polyethylenimine-based non-viral gene delivery systems Eur. J. Pharm. Biopharm. 2005 247 266
147. T. Liu, X. Yu, B. Kan, Q. Guo, X. Wang, and S. Shi Enhanced gene delivery using biodegradable poly(ester amine)s (PEAs) based on low-molecular- weight polyethylenimine and poly(epsilon-caprolactone)-pluronic- poly(epsilon- caprolactone) J. Biomed. Nanotechnol. 6 4 2010 351 359
148. M. Neu, D. Fischer, and T. Kissel Recent advances in rational gene transfer vector design based on poly (ethylene imine) and its derivatives J. Gene Med. 7 2005 992 1009
149. R. Deng, Y. Yue, F. Ji, Y. Chen, H.-F. Kung, and M.C.M. Lin Revisit the complexation of PEI and DNA-how to make low cytotoxic and highly efficient PEI gene transfection non-viral vectors with a controllable chain length and structure? J. Control. Release 140 2009 40 46
150. H. Huang, H. Yu, G. Tang, Q. Wang, and J. Li Low molecular weight polyethylenimine cross-linked by 2-hydroxypropyl-gamma-cyclodextrin coupled to peptide targeting HER2 as a gene delivery vector Biomaterials 31 2011 1830 1838
151. K. Liu, S. Wang, W. Fan, Q. Zhu, I. Yang, and S. Gao Degradable polyethylenimine derivate coupled to a bifunctional peptide R13 as a new gene-delivery vector Int. J. Nanomed. 7 2012 1149 1162
152. Putnam D. Polymers for gene delivery across length scales Nat. Mater. 5 2006 439 451
153. D.W. Pack, A.S. Hoffman, S. Pun, and P.S. Stayton Designand development of polymers for gene delivery Nat. Rev. Drug Discov. 4 2005 581 593
154. J.J. Green, G.T. Zugates, N.C. Tedford, Y. Huang, L.G. Griffith, and D.A. Lauffenburger Combinatorial modification of degradable polymers enables trans- fection of human cells comparable to adenovirus Adv. Mater. 19 2007 2836 2842
155. K.C. Wood, S.M. Azarin, W. Arap, R. Pasqualini, R. Langer, and P.T. Hammond Tumor- targeted gene delivery using molecularly engineered hybrid polymers functionalized with a tumor-homing peptide Bioconjug. Chem. 19 2008 403 405
156. M. Thomas, and A.M. Klibanov Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells Proc. Natl. Acad. Sci. U. S. A. 99 2002 14640 14645
157. S. Srinivasachari, Y. Liu, L.E. Prevette, and T.M. Reineke Effects of trehalose click polymer length on pDNA complex stability and delivery efficacy Biomaterials 28 2007 2885 2898
158. F. Alexis, E. Pridgen, L.K. Molnar, and O.C. Farokhzad Factors affecting the clearance and bio-distribution of polymeric nanoparticles Mol. Pharm. 5 2008 505 515
159. T.J. Harris, J.J. Green, P.W. Fung, R. Langer, D.G. Anderson, and S.N. Bhatia Tissue-specific gene delivery via nanoparticle coating Biomaterials 31 2010 998 1006
160. E. Buhleier, E. Wehner, and F. Vogtle Synthesis 78 1978
161. D.A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, and P. Smith A new class of polymers - starburst-dendritic macromolecules Polym. J. 17 1985 117 132
162. D.A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, and P. Smith Dendritic macromolecules - synthesis of starburst dendrimers Macromolecules 19 1986 2466 2468
163. G.R. Newkome, Z.Q. Yao, G.R. Baker, V.K. Gupta, P.S. Russo, and M.J. Saunders Cascade molecules: 2. Synthesis and characterization of a benzene [9]3-arborol J. Am. Chem. Soc. 108 1986 849 850
164. G.R. Newkome, Z.Q. Yao, G.R. Baker, and V.K. Gupta Micelles: Cascade molecules - a new approach to micelles - a [27]-arborol J. Org. Chem. 50 1985 2003 2004
165. M.A. Liu Immunologic basis of vaccine vectors Immunity 33 2010 504 515
166. G. Leroux-Roels Unmet needs in modern vaccinology: adjuvants to improve immune response Vaccine 28 Suppl. 3 2010 C25 C36
167. G.A. Pietersz, C.K. Tang, and V. Apostolopoulos Structure and design of polycationic carriers for gene delivery Mini Rev. Med. Chem. 6 2006 1285 1298
168. R.K. Tekade, P.V. Kumar, and N.K. Jain Dendrimers in oncology: an expanding horizon Chem. Rev. 109 2009 49 87
169. M.G. Agadjanyan, A. Ghochikyan, I. Petrushina, V. Vasilevko, N. Movsesyan, and M. Mkrtichyan Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide J. Immunol. 174 2005 1580 1586